{"content":[{"text":"Ovid Therapeutics Receives “Company \n Making a Difference Award” from \n CDKL5 Deficiency Disorder \n Community","bbox":{"left":0.117686,"top":0.111162,"width":0.741044,"height":0.15957900000000003}},{"text":"NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics \n Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing \n medicines that transform the lives of people with rare neurological diseases, \n today announced it has received the 2018 CDKL5 Forum Company Making a \n Difference Award for initiation of the Phase 2 ARCADE trial with OV935/TAK- \n 935, and its commitment to the CDKL5 deficiency disorder (CDD) patient \n community. The award was announced today in London, UK at the CDKL5 \n Forum, the largest annual conference on the advancement of science and \n therapeutic development for CDD. \n CDD is a rare, severe, neurological disorder that causes frequent, treatment- \n resistent seizures in the first few months of life. CDD results in a constellation \n of severe challenges, including developmental delay and intellectual disability, \n movement disorder, difficulty sleeping, scoliosis, visual impairment, \n microcephaly and various gastrointestinal difficulties. There are currently \n no FDA-approved therapies for CDD. \n “We hand out the Company Making a Difference Award annually to recognize \n industry partners for their commitment and support, and this year we are \n pleased to recognize the team at Ovid Therapeutics,” said Ana Mingorance, \n Ph.D., chief development officer of Loulou Foundation. “Since the day Ovid \n selected CDD as a condition to pursue, they have shown amazing support \n and care for our community, and we are excited to partner with such a human- \n centric organization.” \n The ARCADE trial is a Phase 2 multi-center, open-label, pilot study designed \n to evaluate the treatment of OV935 in pediatric patients with epileptic seizures \n associated with CDD or Duplication 15q (Dup15q) syndrome. The first \n patients have already been enrolled into ARCADE. This study is part of a \n global collaboration with Takeda Pharmaceutical Company Limited.","bbox":{"left":0.117686,"top":0.3209,"width":0.76417,"height":0.5758559999999999}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}